title: Six-year follow up of imatinib therapy for newly diagnosed chronic myeloid leukemia in Iranian patients.
abstract: BACKGROUND
  The present study reported a six-year follow up of patients with chronic myeloid leukemia who were on imatinib therapy.
  
  
  METHODS
  We performed a retrospective study on a total of 417 patients diagnosed with chronic-phase, Philadelphia-positive (Ph+) chronic myeloid leukemia within six months before study entry. Patients were eligible for the study if they were between 18 and 70 years of age. Enrolled patients were treated at an initial dose of 400 mg of imatinib.
  
  
  RESULTS
  The mean age of 417 patients was 40.9±14.5 years; 220 (52%) were men and 197 (47.2%) were women. Complete hematologic response at three months occurred in 99% of patients, 221 (53%) before four weeks and 196 (47%) after four weeks. Adverse events occurred in 17 (4.1%) of patients, relapse in 46 (11%) and death in 31 (7.4%) of our studied population. At 72 months, the estimated rate of overall survival rate was 89%.
  
  
  CONCLUSIONS
  Our findings showed the efficacy and safety of imatinib mesylate among Iranian patients with chronic myeloid leukemia by hematological and molecular response.
authors: Department of Blood and Research Center, AJA University of Medical Science, Tehran, Iran.
authors: Hassan
authors: H
authors: Jalaeikhoo
authors: Ahmad
authors: A
authors: Ahmadzadeh
authors: Gholamreza
authors: G
authors: Toogeh
authors: Habib
authors: H
authors: Haybar
authors: Armita
authors: A
authors: Valizadeh
authors: Ramazan
authors: R
authors: Charoosaei
authors: Mehdi
authors: M
authors: Yadollahzadeh
authors: Manouchehr
authors: M
authors: Keyhani
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007492:Iran; D053208:Kaplan-Meier Estimate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate